Wrap Text
Notification of transactions by persons discharging managerial responsibilities and persons closely associated
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")
5 June 2018
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
Vesting of awards under the Company's Forfeitable Share Plan
Awards of ordinary shares in Mediclinic (the "Shares") under the Mediclinic International Limited
Forfeitable Share Plan ("FSP") granted in June 2015 vested on 1 June 2018.
The table below sets out the number of shares vested for Directors and other persons discharging
managerial responsibilities ("PDMRs") who were granted awards under the scheme, together with any
disposals made to satisfy their tax liabilities arising on vesting or for other reasons. Mr Danie Meintjes
sold the minimum number of shares required to satisfy any tax liability arising on vesting. All shares
were sold at a price of ZAR106.91 per Share.
Name Director/ PDMR Number of Number of Number of
JSE Shares Shares sold Shares
vested retained
Danie Meintjes Director 33 949 15 786 18 163
David Hadley PDMR 7 185 7 185 0
Gert Hattingh PDMR 10 094 4 693 5 401
Koert Pretorius PDMR 13 241 13 241 0
Dr Dirk le Roux PDMR 5 828 5 828 0
Dr Ole Wiesinger1 PDMR 12 156 n/a n/a
Notes:
1. Dr Wiesinger was granted a conditional right to 12 156 Shares under the Country Schedule to the Forfeitable
Share Plan in June 2015, receivable in cash or Shares on vesting, at Dr Wiesinger’s option. On 1 June 2018,
Dr Wiesinger elected to receive the equivalent value of the vested shares in cash.
The performance conditions for awards made under the FSP were tested following the change of control
in Mediclinic International Limited, resulting from its reverse takeover of Al Noor Hospitals Group Plc.
The corresponding awards vested on the original vesting date.
The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.
1. Details of PDMR/person closely associated with them (“PCA”)
a) Name Daniël Petrus Meintjes
2. Reason for the notification
a) Position/status Executive Director of the Company
b) Initial notification/Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting of award over ordinary shares granted under the
transaction Company’s Forfeitable Share Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
Nil cost 33 949
d) Aggregated
information
Aggregated volume 33 949
Price Nil cost
e) Date of the 1 June 2018
transaction
f) Place of the Johannesburg Stock Exchange
transaction
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Sale of shares vested under the Company’s Forfeitable Share Plan
transaction to cover tax liabilities arising on vesting
c) Price(s) and
volume(s) Price(s) Volume(s)
ZAR 106.91 15 786
d) Aggregated
information
Aggregated volume 15 786
Price ZAR 106.91
e) Date of the 1 June 2018
transaction
f) Place of the Johannesburg Stock Exchange
transaction
1. Details of PDMR/person closely associated with them (“PCA”)
a) Name David John Hadley
2. Reason for the notification
a) Position/status Chief Executive Officer – Mediclinic Middle East
b) Initial notification/Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code B00B8HX8Z88
b) Nature of the Vesting of award over ordinary shares granted under the
transaction Company’s Forfeitable Share Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
Nil cost 7 185
d) Aggregated
information
Aggregated volume 7 185
Price Nil cost
e) Date of the 1 June 2018
transaction
f) Place of the Johannesburg Stock Exchange
transaction
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Sale of shares vested under the Company’s Forfeitable Share Plan
transaction
c) Price(s) and
volume(s) Price(s) Volume(s)
ZAR 106.91 7 185
d) Aggregated
information
Aggregated volume 7 185
Price ZAR 106.91
e) Date of the 1 June 2018
transaction
f) Place of the Johannesburg Stock Exchange
transaction
1. Details of PDMR/person closely associated with them (“PCA”)
a) Name Gert Cornelis Hattingh
2. Reason for the notification
a) Position/status Chief Corporate Services Officer of the Mediclinic Group
b) Initial notification/Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting of award over ordinary shares granted under the
transaction Company’s Forfeitable Share Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
Nil cost 10 094
d) Aggregated
information
Aggregated volume 10 094
Price Nil cost
e) Date of the 1 June 2018
transaction
f) Place of the Johannesburg Stock Exchange
transaction
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Sale of shares vested under the Company’s Forfeitable Share Plan
transaction to cover tax liabilities arising on vesting
c) Price(s) and
volume(s) Price(s) Volume(s)
ZAR 106.91 4 693
d) Aggregated
information
Aggregated volume 4 693
Price ZAR 106.91
e) Date of the 1 June 2018
transaction
f) Place of the Johannesburg Stock Exchange
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Koert Hendrik Stefanus Pretorius
2. Reason for the notification
a) Position/status Chief Executive Officer – Mediclinic Southern Africa
b) Initial notification/Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting of award over ordinary shares granted under the
transaction Company’s Forfeitable Share Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
Nil cost 13 241
d) Aggregated
information
Aggregated volume 13 241
Price ZAR 106.91
e) Date of the 1 June 2018
transaction
f) Place of the Johannesburg Stock Exchange
transaction
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Sale of shares vested under the Company’s Forfeitable Share Plan
transaction
c) Price(s) and
volume(s) Price(s) Volume(s)
ZAR 106.91 13 241
d) Aggregated
information
Aggregated volume 13 241
Price ZAR 106.91
e) Date of the 1 June 2018
transaction
f) Place of the Johannesburg Stock Exchange
transaction
1. Details of PDMR/person closely associated with them ("PCA")
a) Name Dr Dirk Cornelius le Roux
2. Reason for the notification
a) Position/status Chief Information Officer of the Mediclinic Group
b) Initial notification/Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting of award over ordinary shares granted under the
transaction Company’s Forfeitable Share Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
Nil cost 5 828
d) Aggregated
information
Aggregated volume 5 828
Price Nil cost
e) Date of the 1 June 2018
transaction
f) Place of the Johannesburg Stock Exchange
transaction
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Sale of shares vested under the Company’s Forfeitable Share Plan
transaction
c) Price(s) and
volume(s) Price(s) Volume(s)
ZAR 106.91 5 828
d) Aggregated
information
Aggregated volume 5 828
Price ZAR 106.91
e) Date of the 1 June 2018
transaction
f) Place of the Johannesburg Stock Exchange
transaction
1. Details of PDMR/person closely associated with them (“PCA”)
a) Name Dr Thorsten Ole Wiesinger
2. Reason for the notification
a) Position/status Chief Executive Officer – Hirslanden
b) Initial notification/Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting of award over ordinary shares granted under the
transaction Company’s Forfeitable Share Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
Nil cost 12 156
d) Aggregated
information
Aggregated volume 12 156
Price Nil cost
e) Date of the 1 June 2018
transaction
f) Place of the Johannesburg Stock Exchange
transaction
About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in Switzerland,
Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to
enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary
healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed
and UK-based private healthcare group.
Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities
and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates
49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100
inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than
700 inpatient beds in the United Arab Emirates.
Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary
listings on the JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 05/06/2018 01:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
